Xinhua Pharmaceutical's Stock Rises Over 4% on Middle East Export Partnership for Ethyl Icosapentate Soft Capsules

Stock News07-13

Shandong Xinhua Pharmaceutical Co., Ltd. (HKEX: 00719) saw its share price increase by more than 4%. At the time of writing, the stock was up 3.79% to HK$6.02, with a turnover of HK$9.99 million.

Kexing Biopharm Co.,Ltd. announced via its official social media account that it has once again partnered with Shandong Xinhua Pharmaceutical Co., Ltd. (referred to as "Xinhua Pharmaceutical") to export Ethyl Icosapentate soft capsules to Saudi Arabia and the United Arab Emirates.

This collaboration marks another significant partnership between the two companies following their work on Sevelamer Carbonate tablets, jointly aiming to introduce domestically produced high-purity EPA formulations into two major core pharmaceutical markets in the Middle East.

Xinhua Pharmaceutical's Ethyl Icosapentate soft capsules received a Drug Registration Certificate from the National Medical Products Administration in June 2025, achieving full-chain independent control from raw materials to finished formulations for the domestic EPA product.

Currently, a registration application for this drug has been submitted to the U.S. Food and Drug Administration (FDA).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109718693?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-13 14:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109718693","market":"nz","top_or_hot":-1,"title":"Xinhua Pharmaceutical's Stock Rises Over 4% on Middle East Export Partnership for Ethyl Icosapentate Soft Capsules","media":"Stock News","content":"<p><b>Shandong Xinhua Pharmaceutical Co., Ltd.</b> (<b>HKEX: 00719</b>) saw its share price increase by more than 4%. At the time of writing, the stock was up 3.79% to HK$6.02, with a turnover of HK$9.99 million.<br><br>\n<b>Kexing Biopharm Co.,Ltd.</b> announced via its official social media account that it has once again partnered with Shandong Xinhua Pharmaceutical Co., Ltd. (referred to as \"Xinhua Pharmaceutical\") to export Ethyl Icosapentate soft capsules to Saudi Arabia and the United Arab Emirates.<br><br>\nThis collaboration marks another significant partnership between the two companies following their work on Sevelamer Carbonate tablets, jointly aiming to introduce domestically produced high-purity EPA formulations into two major core pharmaceutical markets in the Middle East.<br><br>\nXinhua Pharmaceutical's Ethyl Icosapentate soft capsules received a Drug Registration Certificate from the National Medical Products Administration in June 2025, achieving full-chain independent control from raw materials to finished formulations for the domestic EPA product.<br><br>\nCurrently, a registration application for this drug has been submitted to the U.S. Food and Drug Administration (FDA).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xinhua Pharmaceutical's Stock Rises Over 4% on Middle East Export Partnership for Ethyl Icosapentate Soft Capsules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXinhua Pharmaceutical's Stock Rises Over 4% on Middle East Export Partnership for Ethyl Icosapentate Soft Capsules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-13 14:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Shandong Xinhua Pharmaceutical Co., Ltd.</b> (<b>HKEX: 00719</b>) saw its share price increase by more than 4%. At the time of writing, the stock was up 3.79% to HK$6.02, with a turnover of HK$9.99 million.<br><br>\n<b>Kexing Biopharm Co.,Ltd.</b> announced via its official social media account that it has once again partnered with Shandong Xinhua Pharmaceutical Co., Ltd. (referred to as \"Xinhua Pharmaceutical\") to export Ethyl Icosapentate soft capsules to Saudi Arabia and the United Arab Emirates.<br><br>\nThis collaboration marks another significant partnership between the two companies following their work on Sevelamer Carbonate tablets, jointly aiming to introduce domestically produced high-purity EPA formulations into two major core pharmaceutical markets in the Middle East.<br><br>\nXinhua Pharmaceutical's Ethyl Icosapentate soft capsules received a Drug Registration Certificate from the National Medical Products Administration in June 2025, achieving full-chain independent control from raw materials to finished formulations for the domestic EPA product.<br><br>\nCurrently, a registration application for this drug has been submitted to the U.S. Food and Drug Administration (FDA).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1109718693","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109718693","pubTimestamp":1783924132,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shandong Xinhua Pharmaceutical Co., Ltd. (HKEX: 00719) saw its share price increase by more than 4%. At the time of writing, the stock was up 3.79% to HK$6.02, with a turnover of HK$9.99 million....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688136":"科兴制药","BK1191":"制药","KCAI":"KraneShares China Alpha Index ETF","BK0239":"医药制造","VXUS":"国际股票ETF-Vanguard","00719":"山东新华制药股份","BK1515":"抗疫概念","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"translate_title":"新华制药二十碳五酸乙酯软胶囊中东出口合作伙伴关系股价上涨逾4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688136":1,"00719":1,"KCAI":1,"VXUS":1},"content_text":"Shandong Xinhua Pharmaceutical Co., Ltd. (HKEX: 00719) saw its share price increase by more than 4%. At the time of writing, the stock was up 3.79% to HK$6.02, with a turnover of HK$9.99 million.\nKexing Biopharm Co.,Ltd. announced via its official social media account that it has once again partnered with Shandong Xinhua Pharmaceutical Co., Ltd. (referred to as \"Xinhua Pharmaceutical\") to export Ethyl Icosapentate soft capsules to Saudi Arabia and the United Arab Emirates.\nThis collaboration marks another significant partnership between the two companies following their work on Sevelamer Carbonate tablets, jointly aiming to introduce domestically produced high-purity EPA formulations into two major core pharmaceutical markets in the Middle East.\nXinhua Pharmaceutical's Ethyl Icosapentate soft capsules received a Drug Registration Certificate from the National Medical Products Administration in June 2025, achieving full-chain independent control from raw materials to finished formulations for the domestic EPA product.\nCurrently, a registration application for this drug has been submitted to the U.S. Food and Drug Administration (FDA).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109718693","isCrawlerRequest":true}